A

ANI Pharmaceuticals
D

ANIP

57.580
USD
-0.78
(-1.34%)
مفتوح الان
حجم التداول
656
الربح لكل سهم
6
العائد الربحي
-
P/E
-123
حجم السوق
1,210,203,485
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    C
    CAH
    -0.060
    (-0.05%)
    127.810 USD
    H
    HSIC
    0.430
    (0.58%)
    74.600 USD
    I
    ICLR
    -0.490
    (-0.24%)
    204.660 USD
    IDXX
    IDXX
    2.67
    (0.63%)
    429.77 USD
    L
    LH
    -0.160
    (-0.07%)
    243.840 USD
    P
    PAHC
    -0.340
    (-1.58%)
    21.170 USD
    P
    PRGO
    -0.170
    (-0.70%)
    24.280 USD
    ZBH
    ZBH
    -0.200
    (-0.18%)
    110.400 USD
    ZTS
    ZTS
    -0.860
    (-0.51%)
    166.640 USD
    المزيد
الأخبار
المقالات

العنوان: ANI Pharmaceuticals

القطاع: Healthcare
الصناعة: Drug Manufacturers - Specialty & Generic
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.